Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | MEN1 | O00255 | 2/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | HPGD | P15428 | 2/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | GAA | P10253 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9001249 | 0.78 | ALDH1A1 (0.33) | ALDH1A1MEN1KMT2AHPGDMAPT | |
| SCHEMBL31756427 | 0.77 | KMT2A (0.33) | ALDH1A1MEN1KMT2AHPGDMAPT | |
| SCHEMBL2241228 | 0.73 | ALDH1A1 (0.50) | ALDH1A1MEN1KMT2AHPGDPKM | |
| Trifluoromethanesulfonic Acid SCHEMBL17221076 | 0.72 | MEN1 (0.40) | ALDH1A1MEN1KMT2AHPGDPKM | |
| SCHEMBL35211650 | 0.69 | GABRP (0.33) | — | |
| SCHEMBL24315621 | 0.67 | — | — | |
| SCHEMBL5911639 | 0.67 | LMNA (0.47) | ALDH1A1MEN1KMT2AHPGDPKM | |
| SCHEMBL18320262 | 0.67 | FFAR3 (0.39) | ALDH1A1MEN1KMT2AHPGDPKM | |
| SCHEMBL6220624 | 0.66 | GABRP (0.31) | — | |
| SCHEMBL31756580 | 0.66 | MAPK1 (0.37) | ALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2026-01-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20260001877-A1 | HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN | CNR1, SCN1B, OPRL1 | ALDH1A1 1503/4885MEN1 4167/4885KMT2A 3937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.